Report cover image

Parkinson’s disease drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Jan 01, 2025
Length 133 Pages
SKU # FOB19554713

Description

Growth Factors of Parkinson's Disease Drugs Market

The Parkinson's disease drugs market size was valued at USD 4,500.0 million in 2018, and the market is now projected tgrow from USD 13,580.0 million by 2032, exhibiting a CAGR of 8.2% during the forecast period of 2019-2032.

Hoffmann-La Roche Ltd. and UCB S.A. were the market leaders in 2018 because of the drastic sales of Madopar and Neupro. These collaborations further improved the Parkinson's disease drugs market growth. The third spot is found with Acadia Pharmaceuticals, which landed the position because of the requisites of Nuplazid. Expectedly, the share of Acadia would rise more with the uptake of INBRIJA in FY 2019. Important players outside Acadia include Pfizer, Merck, Teva, Orion Pharma and Lundbeck. Since this therapy has rejuvenated the 2019 fiscal year, therefore, a rise in Acadia's stake would be expected.

In the same year, this market share for decarboxylase inhibitors-cabridopa and levodopa-cumbrance management was 37.8, which can be said tlead. It is now nowadays Levodopa as the most prevailing therapy for Parkinson's disease. An increased clinical trial with the implantation of RYTARY by Impax Laboratories stimulates the Parkinson's disease drugs market share. It is expected tbe the largest CAGR during this timeframe. Consequently, there would be an overall growth in demand around the market.

Comprehensive Analysis of Parkinson's Disease Drugs Market

The Parkinson's disease drugs market and healthcare industry is rising at an exponential rate due tits market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated by Drug Class, by Route of Administration and by Distribution Channels. The Drug Class includes, Decarboxylase Inhibitors, Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor and Catechol-O-Methyltransferase (COMT) Inhibitors. The Route of Administration includes, Oral, Injection and Transdermal. The Distribution Channels includes hospitals and Hospital Pharmacy, Retail Pharmacy and Online Pharmacy.

Europe dominates the global Parkinson’s disease market in terms of maximum revenue of USD 1,540.7 million in 2018 majorly because of amplified incidences of Parkinson’s disease, and enhanced support from the government through government-supported pharmacies. However, better research and development spending and projected approval and launch of some pipeline drug candidates are expected tmove the maximum share of the Parkinson’s disease drugs market tNorth America by the end of 2026.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Pfizer, Inc., Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Orion Pharma, UCB S.A, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc., Impax Laboratories, Inc., Lundbeck A/S and Other players. These market players provide a level-playing competitive landscape.

In May 2021, The U.S. FDA granted investigational new drug designation tPharmaTher for ketamine in LD-induced dyskinesias in Parkinsonian patients. This approval will alsunblock paths for PharmaTher tconduct the phase II clinical trial in treating low-dose Ketamine.

Segmentation Table

Global Parkinson's Disease Drugs Market Scope

By Drug Class

Decarboxylase Inhibitors

Dopamine Agonists

Monoamine Oxidase Type B (MAO-B) Inhibitor

Catechol-O-Methyltransferase (COMT) Inhibitors

Others

By Route of Administration

Oral

Injection

Transdermal

By Distribution Channels

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Geography

North America (USA and Canada)

Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

Latin America (Brazil, Mexicand Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Contents

133 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. 3.4 Market Trends
5. Key Insights
6. 4.1 Prevalence of Parkinson's Disease - For Key Countries, 2018
7. 4.2 Regulatory Scenario - For Key Countries
8. 4.3 Patent Snapshot
9. 4.3 New Product Launch
10. 4.4 Pipeline Analysis
11. 4.5 Key Industry Developments -Mergers, Acquisitions and Partnerships
12. 5. Global Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025
13. 5.1. Key Findings / Summary
14. 5.2. Market Analysis, Insights and Forecast – By Drug Class
15. 5.2.1 Decarboxylase Inhibitors
16. 5.2.2 DopamineAgonists
17. 5.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
18. 5.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
19. 5.2.5 Others
20. 5.3. Market Analysis, Insights and Forecast – By Route of Administration
21. 5.3.1 Oral
22. 5.3.2 Injection
23. 5.3.3 Transdermal
24. 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
25. 5.4.1 Hospital Pharmacy
26. 5.4.2 Retail Pharmacy
27. 5.4.3 Online Stores
28. 5.5. Market Analysis, Insights and Forecast – By Region
29. 5.5.1 North America
30. 5.5.2 Europe
31. 5.5.3 Asia Pacific
32. 5.5.4 Latin America
33. 5.5.5 Middle East & Africa
34. 6. North America Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025
35. 6.1. Key Findings / Summary
36. 6.2. Market Analysis – By Drug Class
37. 6.2.1 Decarboxylase Inhibitors
38. 6.2.2 Dopamine Agonists
39. 6.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
40. 6.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
41. 6.2.5 Others
42. 6.3. Market Analysis – By Route of Administration
43. 6.3.1 Oral
44. 6.3.2 Injection
45. 6.3.3 Transdermal
46. 6.4. Market Analysis – By Distribution Channel
47. 6.4.1 Hospital Pharmacy
48. 6.4.2 Retail Pharmacy
49. 6.4.3 Online Stores
50. 6.5. Market Analysis – By Country
51. 6.5.1 U.S.
52. 6.5.2 Canada
53. 7. Europe Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025
54. 7.1. Key Findings / Summary
55. 7.2. Market Analysis – By Drug Class
56. 7.2.1 Decarboxylase Inhibitors
57. 7.2.2 Dopamine Agonists
58. 7.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
59. 7.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
60. 7.2.4 Others
61. 7.3. Market Analysis – By Route of Administration
62. 7.3.1 Oral
63. 7.3.2 Injection
64. 7.3.3 Transdermal
65. 7.4. Market Analysis – By Distribution Channel
66. 7.4.1 Hospitals
67. 7.4.2 Retail Pharmacy
68. 7.4.3 Online Stores
69. 7.5. Market Analysis – By Countries/ Sub regions
70. 7.5.1 U.K.
71. 7.5.2 Germany
72. 7.5.3 France
73. 7.5.4 Italy
74. 7.5.5 Spain
75. 7.5.6 Scandinavia
76. 7.5.7 Rest of Europe
77. 8. Asia Pacific Parkinson's Disease Drugs Market Analysis, Insights and Forecast,2014-2025
78. 8.1. Key Findings / Summary
79. 8.2. Market Analysis – By Drug Class
80. 8.2.1 Decarboxylase Inhibitors
81. 8.2.2 Dopamine Agonists
82. 8.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
83. 8.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
84. 8.2.5 Others
85. 8.3. Market Analysis – By Route of Administration
86. 8.3.1 Oral
87. 8.3.2 Injection
88. 8.3.3 Transdermal
89. 8.4. Market Analysis – By Distribution Channel
90. 8.4.1 Hospitals
91. 8.4.2 Retail Pharmacy
92. 8.4.3 Online Stores
93. 8.5. Market Analysis – By Countries/ Sub regions
94. 8.5.1 Japan
95. 8.5.2 China
96. 8.5.3 India
97. 8.5.4 Australia
98. 8.5.5 Southeast Asia
99. 8.5.6 Rest of Asia Pacific
100. 9. Latin America Parkinson's Disease Drugs Market Analysis, Insights and Forecast,2014-2025
101. 9.1. Key Findings / Summary
102. 9.2. Market Analysis – By Drug Class
103. 9.2.1 Decarboxylase Inhibitors
104. 9.2.2 Dopamine Agonists
105. 9.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
106. 9.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
107. 9.2.5 Others
108. 9.3. Market Analysis – By Route of Administration
109. 9.3.1 Oral
110. 9.3.2 Injection
111. 9.3.3 Transdermal
112. 9.4. Market Analysis – By Distribution Channel
113. 9.4.1 Hospitals
114. 9.4.2 Retail Pharmacy
115. 9.4.3 Online Stores
116. 9.5. Market Analysis – By Countries/ Sub regions
117. 9.5.1 Brazil
118. 9.5.2 Mexico
119. 9.6.3 Rest of Latin America
120. 10. Middle East &Africa Parkinson's Disease Drugs Market Analysis, Insights and Forecast,2014-2025
121. 10.1. Key Findings / Summary
122. 10.2. Market Analysis – By Drug Class
123. 10.2.1 Decarboxylase Inhibitors
124. 10.2.2 Dopamine Agonists
125. 10.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
126. 10.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
127. 10.2.5 Others
128. 10.3. Market Analysis – By Route of Administration
129. 10.3.1 Oral
130. 10.3.2 Injection
131. 10.3.3 Transdermal
132. 10.4. Market Analysis – By Distribution Channel
133. 10.4.1 Hospitals
134. 10.4.2 Retail Pharmacy
135. 10.4.3 Online Stores
136. 10.5. Market Analysis – By Countries/ Sub regions
137. 10.5.1 South Africa
138. 10.5.2 GCC
139. 10.5.3 Rest of Middle East & Africa
140. 11. Competitive Analysis
141. 11.1. Key Industry Developments
142. 11.2. Global Market Share Analysis (2018)
143. 11.3. Competition Dashboard
144. 11.4. Comparative Analysis –Major Players
145. 11.5. Company Profiles (Overview,Drug Classes & services, SWOT analysis, Recent developments, strategies,financials (based on availability))
146. 11.5.1 UCB S.A
147. 11.5.2 Pfizer,Inc.
148. 11.5.3 F.Hoffmann-La Roche Ltd
149. 11.5.4 Merck& Co., Inc.
150. 11.5.5 Novartis AG
151. 11.5.6 OrionPharma
152. 11.5.7 TevaPharmaceutical Industries Ltd.
153. 11.5.8 Vertical Pharmaceuticals, LLC
154. 11.5.9 ACADIAPharmaceuticals Inc.
155. 11.5.10 ImpaxLaboratories, Inc.
156. 11.5.11 H.Lundbeck A/S
157. 11.5.12 OtherProminent Players
158. 12. Strategic Recommendations
"

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us